Atorvastatin in Management of Newly Diagnosed ITP

• Status: Not yet recruiting
• Trial end date: 2023-12-01

Summary

The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of atorvastatin for the treatment of adults with immune thrombocytopenia (ITP).

• Phase: Phase 2/Phase 3

Details

• Lead Sponsor: Shandong University
• Treatments: Atorvastatin; Calcium; Calcium, Dietary; Dexamethasone